133 related articles for article (PubMed ID: 24092864)
21. The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro.
Descamps V; Helle F; Louandre C; Martin E; Brochot E; Izquierdo L; Fournier C; Hoffmann TW; Castelain S; Duverlie G; Galmiche A; François C
Antiviral Res; 2015 Jun; 118():93-102. PubMed ID: 25823619
[TBL] [Abstract][Full Text] [Related]
22. Identification of a series of 1,3,4-trisubstituted pyrazoles as novel hepatitis C virus entry inhibitors.
Hwang JY; Kim HY; Park DS; Choi J; Baek SM; Kim K; Kim S; Seong S; Choi I; Lee HG; Windisch MP; Lee J
Bioorg Med Chem Lett; 2013 Dec; 23(23):6467-73. PubMed ID: 24125883
[TBL] [Abstract][Full Text] [Related]
23. [Antiviral activity in vitro and pharmacokinetics of HCV entry inhibitor AVR560].
Ivashchenko AV; Iamanushkin PM; Mit'kin OD; Ezhova EV; Korzinov OM; Bulanova EA; Koriakova AG; Vyshemirskaia PV; Bychko VV; Ivashchenko AA
Eksp Klin Farmakol; 2014; 77(10):38-43. PubMed ID: 25518527
[TBL] [Abstract][Full Text] [Related]
24. ["Entry inhibitors" prevent virus access to the cell]].
Fessler B
MMW Fortschr Med; 2015 Mar; 157 Suppl 1():86. PubMed ID: 26012995
[No Abstract] [Full Text] [Related]
25. Secreted Interferon-Inducible Factors Restrict Hepatitis B and C Virus Entry In Vitro.
Xia Y; Cheng X; Blossey CK; Wisskirchen K; Esser K; Protzer U
J Immunol Res; 2017; 2017():4828936. PubMed ID: 28367455
[TBL] [Abstract][Full Text] [Related]
26. A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes.
Haid S; Novodomská A; Gentzsch J; Grethe C; Geuenich S; Bankwitz D; Chhatwal P; Jannack B; Hennebelle T; Bailleul F; Keppler OT; Poenisch M; Bartenschlager R; Hernandez C; Lemasson M; Rosenberg AR; Wong-Staal F; Davioud-Charvet E; Pietschmann T
Gastroenterology; 2012 Jul; 143(1):213-22.e5. PubMed ID: 22465429
[TBL] [Abstract][Full Text] [Related]
27. Locking out hepatitis C.
Gerold G; Rice CM
Nat Med; 2011 May; 17(5):542-4. PubMed ID: 21546968
[No Abstract] [Full Text] [Related]
28. A Novel Inhibitor IDPP Interferes with Entry and Egress of HCV by Targeting Glycoprotein E1 in a Genotype-Specific Manner.
Lee M; Yang J; Jo E; Lee JY; Kim HY; Bartenschlager R; Shin EC; Bae YS; Windisch MP
Sci Rep; 2017 Mar; 7():44676. PubMed ID: 28333153
[TBL] [Abstract][Full Text] [Related]
29. Discovery of highly potent small molecule Hepatitis C Virus entry inhibitors.
Mittapalli GK; Jackson A; Zhao F; Lee H; Chow S; McKelvy J; Wong-Staal F; Macdonald JE
Bioorg Med Chem Lett; 2011 Nov; 21(22):6852-5. PubMed ID: 21978675
[TBL] [Abstract][Full Text] [Related]
30. Entry Inhibitors: A Perspective for Prevention of Hepatitis C Virus Infection in Organ Transplantation.
Colpitts CC; Chung RT; Baumert TF
ACS Infect Dis; 2017 Sep; 3(9):620-623. PubMed ID: 28812869
[TBL] [Abstract][Full Text] [Related]
31. Tannic Acid Inhibits Hepatitis C Virus Entry into Huh7.5 Cells.
Liu S; Chen R; Hagedorn CH
PLoS One; 2015; 10(7):e0131358. PubMed ID: 26186636
[TBL] [Abstract][Full Text] [Related]
32. [Research on hepatitis C virus entry inhibitor].
Zeng Wenting ; Lu X; Wang J; Jin X; Zhu J
Bing Du Xue Bao; 2015 Jan; 31(1):97-105. PubMed ID: 25997338
[TBL] [Abstract][Full Text] [Related]
33. A Novel Class of Small Molecule Compounds that Inhibit Hepatitis C Virus Infection by Targeting the Prohibitin-CRaf Pathway.
Liu S; Wang W; Brown LE; Qiu C; Lajkiewicz N; Zhao T; Zhou J; Porco JA; Wang TT
EBioMedicine; 2015 Nov; 2(11):1600-6. PubMed ID: 26870784
[TBL] [Abstract][Full Text] [Related]
34. Entry inhibitors and future treatment of hepatitis C.
Fofana I; Jilg N; Chung RT; Baumert TF
Antiviral Res; 2014 Apr; 104():136-42. PubMed ID: 24525381
[TBL] [Abstract][Full Text] [Related]
35. Micrococcin P1, a naturally occurring macrocyclic peptide inhibiting hepatitis C virus entry in a pan-genotypic manner.
Lee M; Yang J; Park S; Jo E; Kim HY; Bae YS; Windisch MP
Antiviral Res; 2016 Aug; 132():287-95. PubMed ID: 27387825
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of hepatitis C entry: too soon to dismiss while many are still being denied treatment.
Uprichard SL; Sainz B
Gut; 2015 Apr; 64(4):690-1. PubMed ID: 25287483
[No Abstract] [Full Text] [Related]
37. Continued value in understanding viral kinetic decline during interferon-free therapy for HCV.
Meissner EG
Liver Int; 2015 Feb; 35(2):295-6. PubMed ID: 25424883
[No Abstract] [Full Text] [Related]
38. CD36 is a co-receptor for hepatitis C virus E1 protein attachment.
Cheng JJ; Li JR; Huang MH; Ma LL; Wu ZY; Jiang CC; Li WJ; Li YH; Han YX; Li H; Chen JH; Wang YX; Song DQ; Peng ZG; Jiang JD
Sci Rep; 2016 Feb; 6():21808. PubMed ID: 26898231
[TBL] [Abstract][Full Text] [Related]
39. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry.
Ciesek S; von Hahn T; Colpitts CC; Schang LM; Friesland M; Steinmann J; Manns MP; Ott M; Wedemeyer H; Meuleman P; Pietschmann T; Steinmann E
Hepatology; 2011 Dec; 54(6):1947-55. PubMed ID: 21837753
[TBL] [Abstract][Full Text] [Related]
40. Plant-derived antivirals against hepatitis c virus infection.
Jardim ACG; Shimizu JF; Rahal P; Harris M
Virol J; 2018 Feb; 15(1):34. PubMed ID: 29439720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
